CHRS
Coherus BioSciences
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: CHRS
- PE Ratio
As of Jun 3, 2026, the CHRS stock has a P/E ratio of 0.9. The calculation is based on the latest EPS of $1.64 and the stock price of $1.47 per share. A decrease of 3.2% has been observed in the PE ratio compared to its average of 0.9 of the past four quarters.
CHRS PE ratio history
The mean historical PE ratio of Coherus BioSciences over the last seven years is 5.55. The current 0.9 price-to-earnings ratio is 84% less than the historical average. Analyzing the last seven years, CHRS's PE ratio reached its highest point in the Dec 2019 quarter at 13.96, with a price of $18.01 and an EPS of $1.29. The Jun 2025 quarter saw the lowest point at 0.47, with a price of $0.73 and an EPS of $1.55.
Coherus BioSciences PE ratio by year
Maximum annual decrease: -82.07% in 2025
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 0.99 | -82.07% | $1.42 | $1.43 |
| 2024 | 5.52 | N/A | $1.38 | $0.25 |
| 2023 | N/A | N/A | $3.33 | -$2.53 |
| 2022 | N/A | N/A | $7.92 | -$3.76 |
| 2021 | N/A | N/A | $15.96 | -$3.81 |
| 2020 | 9.39 | -32.74% | $17.38 | $1.85 |
| 2019 | 13.96 | N/A | $18.01 | $1.29 |
| 2018 | N/A | N/A | $9.05 | -$3.22 |
| 2017 | N/A | N/A | $8.8 | -$4.48 |
| 2016 | N/A | N/A | $28.15 | -$3.04 |
| 2015 | N/A | N/A | $22.96 | -$6.01 |
| 2014 | N/A | N/A | $16.32 | -$10.64 |
| 2013 | N/A | N/A | N/A | -$16.1 |
| 2012 | N/A | N/A | N/A | -$15.85 |
Coherus BioSciences PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 1.03 | 4.04% | $1.69 | $1.64 |
| Dec 2025 | 0.99 | -19.51% | $1.42 | $1.43 |
| Sep 2025 | 1.23 | 161.7% | $1.64 | $1.33 |
| Jun 2025 | 0.47 | N/A | $0.73 | $1.55 |
| Mar 2025 | N/A | N/A | $0.81 | -$1.13 |
| Dec 2024 | 5.52 | N/A | $1.38 | $0.25 |
| Sep 2024 | N/A | N/A | $1.04 | -$0.03 |
| Jun 2024 | N/A | N/A | $1.73 | -$0.35 |
| Mar 2024 | N/A | N/A | $2.39 | -$0.73 |
| Dec 2023 | N/A | N/A | $3.33 | -$2.53 |
| Sep 2023 | N/A | N/A | $3.74 | -$2.62 |
| Jun 2023 | N/A | N/A | $4.27 | -$3.32 |
| Mar 2023 | N/A | N/A | $6.84 | -$3.48 |
| Dec 2022 | N/A | N/A | $7.92 | -$3.76 |
| Sep 2022 | N/A | N/A | $9.61 | -$3.59 |
CHRS Price vs fair value
CHRS average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, CHRS's PE ratio is under its 3, 5 and 10-year averages.
PE comparison
With a price to earnings (P/E) of 0.9, CHRS stands lower than the Healthcare sector and the industry average. Looking at the Healthcare sector average of 23.02, Coherus BioSciences's price to earnings (P/E) is 96% lower.
CHRS PE vs peers
CHRS's PE ratio is below its peer stocks AMGN and RGEN.
| Stock name | PE ratio | Market cap |
|---|---|---|
| CHRS Coherus BioSciences Inc | 0.96 | $243.71M |
| AGEN Agenus Inc | 2.04 | $141.17M |
| AMGN Amgen Inc | 23.87 | $186.56B |
| SRPT Sarepta Therapeutics Inc | 27.77 | $1.76B |
| RGEN Repligen Corp | 137.61 | $7.14B |
Frequently asked questions
What is Coherus BioSciences's PE ratio?
The price to earnings ratio for CHRS stock as of Jun 3, 2026, stands at 0.9.
What is the 3-year average PE ratio for Coherus BioSciences (CHRS)?
The 3-year average PE ratio for CHRS stock is 1.85.
What is the 5-year average PE ratio for Coherus BioSciences (CHRS)?
The 5-year average PE ratio for CHRS stock is 1.85.
What is the highest PE ratio for CHRS?
The highest quarterly PE ratio in the last seven years has been 13.96 and it was in the Dec 2019 quarter.
How does the current PE ratio for CHRS compare to its historical average?
CHRS's current price to earnings ratio is 84% below its 7-year historical average.
Why is Coherus BioSciences's PE ratio so low?
CHRS's PE ratio is low because its earnings per share (EPS) is high relative to its stock price.
How is CHRS's PE ratio calculated (Coherus BioSciences PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Jun 3, 2026), Coherus BioSciences's share price is $1.47. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $1.64. Therefore, Coherus BioSciences's price to earnings ratio for today is 0.9. PE RATIO(0.9) = STOCK PRICE($1.47) / TTM EPS($1.64)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.